培美曲塞联合奈达铂化疗对非小细胞肺癌的临床疗效分析

Clinical Efficacy of Pemetrexed Combined with Nedaplatin in the Treatment of Non-Small Cell Lung Cancer

目的观察培美曲塞联合奈达铂化疗对非小细胞肺癌的临床疗效。方法选定该院收治的非小细胞肺癌患者45例,研究时段自2015年9月-2018年8月,对患者资料进行回顾性分析,分组原则以治疗方式差异性为主,分对照组(22例,吉西他滨、奈达铂化疗治疗)、试验组(23例,培美曲塞、奈达铂化疗治疗),比较临床疗效、不良反应和生存期。结果试验组临床总有效率(56.52%)较对照组(45.46%)高,但差异无统计学意义(χ^2=0.203,P=0.652);试验组不良反应发生率(4.35%)显著较对照组(27.27%)低(χ^2=4.999,P=0.034);试验组中位生存期较对照组长(t=6.935,P=0.000),但无进展生存期与对照组相比差异无统计学意义(t=1.755,P=0.086)。结论针对非小细胞肺癌患者,培美曲塞、奈达铂化治疗效果较为理想,不良反应发生率较低,患者耐受性较理想,值得借鉴。

Objective To observe the clinical efficacy of pemetrexed combined with nedaplatin chemotherapy for nonsmall cell lung cancer. Methods Forty-five patients with non-small cell lung cancer admitted to our hospital from September 2015 to August 2018 were selected. The patients’ data were retrospectively analyzed. According to the grouping principle, which was based on the difference of treatment methods, they were divided into control group(22 cases, gemcitabine, nedaplatin chemotherapy), and experimental group(23 cases, pemetrexed, nedaplatin chemotherapy). Clinical efficacy, adverse reactions and survival were compared. Results The total clinical effective rate of the experimental group(56.52%) was higher than that of the control group(45.46%), but there was no statistical difference(χ^2=0.203, P=0.652). The incidence of adverse reactions in the experimental group(4.35%) was significantly lower than that of the control group(27.27%),(χ^2=4.999, P=0.034). The median survival of the experimental group was longer than that of the control group(t=6.935, P=0.000), but there was no statistically significant difference(t=1.755,P=0.086).Conclusion For patients with non-small cell lung cancer, pemetrexed, nedaplatin treatment is more effective, the incidence of adverse reactions is lower, and the patient’s tolerance is ideal, which is worth learning.